has been cited by the following article(s):
|
[1]
|
Opioid growth factor receptor (OGFR) expression is downregulated with progression of triple negative breast cancer
|
|
International Journal of Cancer Therapy and Oncology,
2015 |
|
|
|
|
[2]
|
Lipid‐Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer
|
|
Advanced healthcare materials,
2015 |
|
|
|
|
[3]
|
Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers
|
|
Expert review of anticancer therapy? ,
2014 |
|
|
|
|
[4]
|
Opioid growth factor–opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer
|
|
Experimental Biology and Medicine? ,
2013 |
|
|
|
|
[5]
|
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment
|
|
Investigational new drugs,
2013 |
|
|
|
|
[6]
|
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer
|
|
Experimental Biology and Medicine,
2013 |
|
|
|
|
[7]
|
Expression of the opioid growth factor–opioid growth factor receptor axis in human ovarian cancer
|
|
Gynecologic oncology? ,
2012 |
|
|
|
|
[8]
|
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer
|
|
Experimental Biology and Medicine,
2012 |
|
|
|
|
[9]
|
Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure
|
|
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology,
2012 |
|
|
|
|
[1]
|
Opioid growth factor receptor (OGFR) expression is downregulated with progression of triple negative breast cancer
International Journal of Cancer Therapy and Oncology,
2015
DOI:10.14319/ijcto.34.7
|
|
|
|
|
[2]
|
Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers
Expert Review of Anticancer Therapy,
2014
DOI:10.1586/14737140.2014.867234
|
|
|
|
|
[3]
|
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment
Investigational New Drugs,
2013
DOI:10.1007/s10637-012-9918-3
|
|
|
|
|
[4]
|
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment
Investigational New Drugs,
2013
DOI:10.1007/s10637-012-9918-3
|
|
|
|
|
[5]
|
Opioid growth factor – opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer
Experimental Biology and Medicine,
2013
DOI:10.1177/1535370213489492
|
|
|
|
|
[6]
|
Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancer
Experimental Biology and Medicine,
2013
DOI:10.1177/1535370213488483
|
|
|
|
|
[7]
|
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer
Experimental Biology and Medicine,
2012
DOI:10.1258/ebm.2011.011321
|
|
|
|
|
[8]
|
Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology,
2012
DOI:10.1152/ajpregu.00670.2011
|
|
|
|
|
[9]
|
Expression of the opioid growth factor–opioid growth factor receptor axis in human ovarian cancer
Gynecologic Oncology,
2012
DOI:10.1016/j.ygyno.2011.10.024
|
|
|
|